1. Academic Validation
  2. GIP1-39, a novel insulinotropic peptide form and aspects on its mechanism of action

GIP1-39, a novel insulinotropic peptide form and aspects on its mechanism of action

  • Regul Pept. 2004 Sep 15;121(1-3):107-12. doi: 10.1016/j.regpep.2004.04.013.
Li Xie 1 Jie Lu Claes-Goran Ostenson Tao Xu Zheng-Wang Chen
Affiliations

Affiliation

  • 1 Institute of Biophysics and Biochemistry, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, PR China.
Abstract

GIP1-39, a novel chain-length form of GIP (gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide), has been purified recently from porcine intestine and found to exist abundantly in this tissue. We have characterized that GIP1-39 is an insulinotropic peptide, and demonstrated that GIP1-39 is more potent in stimulating Insulin secretion from rat pancreatic islets than GIP1-42, the insulinotropic polypeptide reported originally. Therefore, we have further investigated some aspects on the mechanism behind the insulinotropic effect of GIP1-39 in single rat pancreatic beta cells. GIP1-39 at 100 nM was able to significantly increase intracellular Ca2+ concentration ([Ca2+]i), and capable of enhancing exocytosis assessed by membrane capacitance measurement. The novel GIP1-39 might be a more optimal molecular pattern in stimulating Insulin secretion and deserves to be further investigated biologically and clinically.

Figures
Products